Paul La Rosée

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5630187/publications.pdf

Version: 2024-02-01

27 2 papers cit

2,467 citations

430874 18 h-index 30 g-index

34 all docs 34 docs citations

times ranked

34

3264 citing authors

#	Article	IF	CITATIONS
1	Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. Critical Care Medicine, 2022, 50, 860-872.	0.9	29
2	Detecting HLH in hematologic malignancies. Blood, 2022, 139, 961-963.	1.4	2
3	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36, 1870-1878.	7.2	47
4	Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies. Acta Haematologica, 2021, 144, 246-249.	1.4	4
5	Case Report: Hemophagocytic Lymphohistiocytosis and Non-Tuberculous Mycobacteriosis Caused by a Novel GATA2 Variant. Frontiers in Immunology, 2021, 12, 682934.	4.8	6
6	Influence of transfusions, hemodialysis and extracorporeal life support on hyperferritinemia in critically ill patients. PLoS ONE, 2021, 16, e0254345.	2.5	2
7	The impact of specific cytokine directed treatment on severe COVID-19. Leukemia, 2021, 35, 3613-3615.	7.2	3
8	Hemophagocytic Lymphohistiocytosis in Critically Ill Patients. Shock, 2020, 53, 701-709.	2.1	24
9	Hyperferritinemia in Critically Ill Patients*. Critical Care Medicine, 2020, 48, 459-465.	0.9	47
10	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood, 2020, 136, 3051-3055.	1.4	15
11	Treatment and Mortality of Hemophagocytic Lymphohistiocytosis in Adult Critically Ill Patients: A Systematic Review With Pooled Analysis. Critical Care Medicine, 2020, 48, e1137-e1146.	0.9	23
12	Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients. Scientific Reports, 2020, 10, 18277.	3.3	25
13	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia, 2020, 34, 1805-1815.	7.2	188
14	Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1065-1077.	2.5	83
15	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Advances, 2020, 4, 925-929.	5.2	8
16	Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Critical Care, 2020, 24, 244.	5.8	70
17	Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood, 2019, 133, 2465-2477.	1.4	587
18	Hemophagocytic Lymphohistiocytosis: Potentially Underdiagnosed in Intensive Care Units. Shock, 2018, 50, 149-155.	2.1	50

#	Article	IF	CITATIONS
19	Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1508-1517.	3.8	112
20	Rescue of Cytokine Storm Due to HLH by Hemoadsorption in a CTLA4-Deficient Patient. Journal of Clinical Immunology, 2017, 37, 273-276.	3.8	45
21	A consensus review on malignancyâ€associated hemophagocytic lymphohistiocytosis in adults. Cancer, 2017, 123, 3229-3240.	4.1	155
22	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology,the, 2017, 4, e510-e523.	4.6	258
23	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227.	4.6	442
24	Alleviating the storm: ruxolitinib in HLH. Blood, 2016, 127, 1626-1627.	1.4	19
25	First prospective clinical trial in adult HLH. Blood, 2015, 126, 2169-2171.	1.4	4
26	Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology American Society of Hematology Education Program, 2015, 2015, 190-196.	2.5	70
27	Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica, 2015, 100, 997-1004.	3.5	135